Somewhat Positive Press Coverage Somewhat Unlikely to Affect Emergent Biosolutions (EBS) Stock Price

News stories about Emergent Biosolutions (NYSE:EBS) have trended somewhat positive recently, according to Accern. The research firm scores the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Emergent Biosolutions earned a news sentiment score of 0.02 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 44.570874971279 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Emergent Biosolutions (NYSE:EBS) opened at $46.94 on Thursday. The company has a current ratio of 7.37, a quick ratio of 6.46 and a debt-to-equity ratio of 0.38. Emergent Biosolutions has a twelve month low of $27.94 and a twelve month high of $47.37. The firm has a market cap of $1,910.81, a P/E ratio of 24.42, a PEG ratio of 1.33 and a beta of 1.24.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.32. Emergent Biosolutions had a net margin of 15.60% and a return on equity of 15.20%. The firm had revenue of $149.43 million during the quarter, compared to analysts’ expectations of $124.55 million. During the same period in the previous year, the company earned $0.56 earnings per share. The firm’s quarterly revenue was up 4.6% on a year-over-year basis. analysts anticipate that Emergent Biosolutions will post 1.58 EPS for the current fiscal year.

EBS has been the subject of several research reports. BidaskClub raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a report on Friday, August 25th. Zacks Investment Research raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $45.00 price objective for the company in a report on Wednesday, October 25th. Finally, Wells Fargo & Company reissued an “outperform” rating and set a $43.00 price objective (up from $41.00) on shares of Emergent Biosolutions in a report on Saturday, September 30th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Emergent Biosolutions has an average rating of “Buy” and an average price target of $46.00.

In related news, Director Ronald Richard sold 1,266 shares of the business’s stock in a transaction that occurred on Wednesday, September 27th. The shares were sold at an average price of $40.00, for a total transaction of $50,640.00. Following the completion of the sale, the director now directly owns 24,676 shares in the company, valued at $987,040. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Adam Havey sold 7,885 shares of the business’s stock in a transaction that occurred on Wednesday, September 27th. The shares were sold at an average price of $39.50, for a total transaction of $311,457.50. Following the sale, the executive vice president now owns 33,931 shares of the company’s stock, valued at $1,340,274.50. The disclosure for this sale can be found here. Insiders have sold 280,989 shares of company stock valued at $11,700,343 over the last three months. 16.50% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.com-unik.info/2017/12/21/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-emergent-biosolutions-ebs-stock-price.html.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

What are top analysts saying about Emergent Biosolutions? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Emergent Biosolutions and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit